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Comparative transcriptomics 
reveals key differences in the 
response to milk oligosaccharides 
of infant gut-associated 
bifidobacteria
Daniel Garrido1,3,5,6, Santiago Ruiz-Moyano1,3, Danielle G. Lemay3,4, David A. Sela1,3,7, 
J. Bruce German2,3 & David A. Mills1,2,3
Breast milk enhances the predominance of Bifidobacterium species in the infant gut, probably due to 
its large concentration of human milk oligosaccharides (HMO). Here we screened infant-gut isolates 
of Bifidobacterium longum subsp. infantis and Bifidobacterium bifidum using individual HMO, and 
compared the global transcriptomes of representative isolates on major HMO by RNA-seq. While 
B. infantis displayed homogeneous HMO-utilization patterns, B. bifidum were more diverse and 
some strains did not use fucosyllactose (FL) or sialyllactose (SL). Transcriptomes of B. bifidum SC555 
and B. infantis ATCC 15697 showed that utilization of pooled HMO is similar to neutral HMO, while 
transcriptomes for growth on FL were more similar to lactose than HMO in B. bifidum. Genes linked 
to HMO-utilization were upregulated by neutral HMO and SL, but not by FL in both species. In 
contrast, FL induced the expression of alternative gene clusters in B. infantis. Results also suggest 
that B. bifidum SC555 does not utilize fucose or sialic acid from HMO. Surprisingly, expression of 
orthologous genes differed between both bifidobacteria even when grown on identical substrates. 
This study highlights two major strategies found in Bifidobacterium species to process HMO, and 
presents detailed information on the close relationship between HMO and infant-gut bifidobacteria.
Breast milk is a complex fluid, shaped by evolution to meet offspring needs regarding nutrition and 
immune protection. Human milk consists of a myriad of molecules with varying structure and abun-
dance, present in a very concentrated form1. Several of these compounds are considered to be bioactive 
agents, potentially playing important roles beyond nutrition by promoting immunological protection and 
stimulating proper development2,3.
Free human milk oligosaccharides (HMO) are among the most abundant components in human 
milk4, after water and lactose. These are carbohydrates with a degree of polymerization from 3 to 
32, composed of five monomers: D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), 
L-fucose (Fuc) and N-acetylneuraminic acid (Neu5Ac, or sialic acid). The combinatory potential of struc-
tural isomers is high, and HMO represent a large catalogue of complex carbohydrates. However, no more 
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than 50 HMO species are normally abundant in an individual mother’s milk5. Major HMO secreted in 
milk include lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and lacto-N-hexaose, which are neu-
tral HMO, in addition to fucosylated molecules such as 2- fucosyllactose (2 FL), 3-fucosyllactose (3FL), 
and lacto-N-fucopentaoses I, II and III5. Finally, sialyl-lacto-N-tetraose, 3′ and 6′ sialyllactose (6SL) are 
examples of acidic HMO6.
Interestingly, the energetic value derived from conventional digestion of these molecules is negligi-
ble for the nursing infant. Intestinal enzymes are incapable of breaking down the majority of complex 
linkages found in HMO7. While initially puzzling for scientists, several major functions have emerged 
and attributed to these molecules. For example, HMO can prevent pathogen binding to the intestinal 
epithelium given their structural similarity with glycoconjugates in the brush border2.
In addition, HMO are substrates for beneficial microbes in the developing infant colon8. Studies have 
consistently shown that the composition of the intestinal microbiome among breast-fed and formula-fed 
infants is different9–11. This is consistent with HMO enriching for the populations capable of efficiently 
utilizing these substrates.
In general, it is understood that species of the Bifidobacterium genus dominate the infant gut micro-
biota in the first year of life12–14. Interestingly, there are only a few bifidobacterial species that are 
consistently isolated from infant feces, including Bifidobacterium longum subsp. longum (B. longum), 
Bifidobacterium longum subsp. infantis (B. infantis), Bifidobacterium breve, and Bifidobacterium bifidum, 
among other lesser taxa11,15–17.
It has been previously shown that certain infant-associated bifidobacteria can utilize HMO purified 
from breast milk as the sole carbon source18. This first suggested potential co-evolution between bifido-
bacteria and their mammalian hosts mediated by milk oligosaccharides. This consumption phenotype 
was observed for some B. infantis and B. bifidum strains19,20, and recently it has been shown that also 
several B. breve can target these molecules, including fucosylated HMO21.
Comparative genomics and functional studies have been very useful in providing a molecular 
framework underlying bifidobacterial HMO utilization, particularly for B. infantis ATCC 1569722 and 
B. bifidum PRL201020. B. infantis deploys a HMO utilization strategy involving translocation of intact 
oligosaccharides using ABC transporters23. Once internalized, milk oligosaccharides are degraded by 
several intracellular glycosyl hydrolases that target linkages inherent to HMO24,25. Released monosaccha-
rides are fermented in the central fructose-6-phosphate phosphoketolase pathway also referred to as the 
“bifid shunt”, resulting in the production of ATP and secretion of acetate and lactate as end products. In 
contrast, the HMO consumption strategy of B. bifidum differs dramatically from B. infantis24. In B. bifi-
dum, HMO are initially processed extracellularly, primarily via secreted glycosyl hydrolases that degrade 
HMO into constituent mono- and disaccharides. B. bifidum then imports the resultant products to be 
catabolized intracellularly through the bifid shunt26.
In order to gain a fundamental understanding of how these two different bifidobacteria have adapted 
to milk oligosaccharide utilization and therefore grow in the infant intestinal environment, it is essential 
to address the diversity of phenotypes found in infant-gut associated strains and also to dissect the global 
transcriptional responses of these microorganisms to individual and chemically different oligosaccha-
rides found in breast milk. In this study, we determined the ability of B. bifidum and B. infantis isolates to 
utilize pooled HMO and the synthetic HMO LNT, LNnT, 2FL, 3FL and 6 SL as well as mucin. In addition, 
we detailed genome-wide transcriptional responses of B. bifidum and B. infantis during growth on these 
HMO substrates as the sole carbon source.
Results
Growth of B. infantis and B. bifidum on pooled and individual HMO. In a previous study, we 
created a collection of 461 Bifidobacterium isolates from 40 breast-fed infant fecal samples21. Among 
these, 297 were identified as B. longum (subsp. infantis or subsp. longum), and 22 as B. bifidum21. In 
order to discriminate these isolates at the strain level, Multilocus Sequencing Typing (MLST) analysis27 
was performed on purified genomic DNA of these isolates as well as 15 other strains obtained from 
culture collections (Table S1). Isolates from unrelated infants that shared identical MLST profiles were 
conservatively considered as separate isolates in this study. The MLST analysis identified 5 B. bifidum 
and 14 new B. infantis strains (Table S1). Together with the collection strains also analyzed, a consensus 
phylogenetic tree of the concatenated MLST data was created (Figure S1). Additional information about 
the MLST analysis is shown in Tables S2–S5.
Previous studies have characterized the HMO utilization phenotype using pooled HMO purified from 
breast milk. Here we evaluated the ability of B. infantis and B. bifidum strains to use individual milk oli-
gosaccharides as a carbon source. We examined strains typed in this study, in addition to other B. infantis 
and B. bifidum collection strains28 (Table S1). In addition to HMO purified from pooled breast milk sam-
ples, we used synthetically generated HMO species such as lacto-N-tetraose (LNT), lacto-N-neotetraose 
(LNnT), 2- fucosyllactose (2 FL), 3- fucosyllactose (3FL), and 6′ sialyllactose (6 SL). These individual HMO 
were selected to represent major structural classes such as neutral non-fucosylated HMO (LNT and 
LNnT), fucosylated HMO (2FL and 3FL), and sialylated HMO (6 SL). The structures of these HMO 
species are depicted in Fig. 1. In addition, all strains were tested for growth on porcine mucin, which is 
a glycosylated protein accesible to certain gut microbes29.
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In general, all B. infantis strains grew to high OD600 values on pooled HMO and every individual 
HMO tested (Table  1). One exception is the utilization pattern of 6 SL, where in a few cases moderate 
or poor growth was observed. In contrast, mucin was not a utilizable substrate for any B. infantis strain, 
results in agreement with previous observations30 for the type strain ATCC 15697 (Table 1).
Interestingly, B. bifidum strains exhibited more phenotypic variability while subsisting on HMO 
(Table  1). Although most strains were capable of utilizing pooled HMO, four of the thirteen strains 
(JCM 1255, JCM 1209, JCM 7004 and S28a) showed little capacity to grow on pooled HMO, LNT, LNnT 
or even mucin (Table  1). JCM 1255 is the type strain and it is known to not represent the growth of 
B. bifidum on HMO31. Utilization of 2 FL, 3FL and 6 SL was also strain-dependent, with several strains 
unable to use 6 SL as the sole carbon source (Table 1).
We performed a principal component analysis (PCA) with the maximum OD600 values of each strain 
growing on every substrate used in the study (Fig. 2). The descriptors HMO, LNT, LNnT, LAC, 2 FL, 3FL 
and 6 SL were mainly explained by the first axis of PCA analysis (Principal component 1) and are clearly 
associated with most of the bifidobacteria strains studied. The clustering of these variables indicates that 
B. infantis and B. bifidum strains grew on HMO similarly to LNT and LNnT. In addition, maximum 
OD600 values on 2 FL, 3FL and 6 SL were more similar to each other (Fig. 2A). The second axis of PCA 
(Principal component 2) was defined by mucin growth and was positively correlated with most of B. 
bifidum strains. In addition, B. infantis strains clustered more tightly together compared to B. bifidum 
strains, which spread in the plot and displayed more variable growth on HMO included in the analysis 
(Fig. 2B). Collectively, these results show that the HMO growth phenotype is mostly conserved among 
B. infantis isolates, and that B. bifidum displays a larger diversity of phenotypes in HMO consumption.
Figure 1. Representative structure of HMO and major oligosaccharides found in breast milk. Dashed 
lines represent glycosidic linkages not found in all HMO.
www.nature.com/scientificreports/
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Genome sequencing of B. bifidum SC555. In order to analyze the global transcriptome of rep-
resentative strains of B. infantis and B. bifidum in response to major milk oligosaccharides, we first 
obtained the genome sequences of representative species. B. infantis ATCC 15697 was chosen due to the 
availability of a completely sequenced genome22 and the conservation of genetic and phenotype observed 
among B. infantis strains here and previous studies28. We sequenced the genome of B. bifidum SC555, a 
strain isolated from breast-fed infant feces, as it exhibited the best growth on HMO fractions tested in 
this study. Genome sequencing of SC555 generated over 40 million reads generated on a Illumina HiSeq 
sequencer. Reads were assembled using the genome of B. bifidum PRL2010 as reference20, annotated and 
Strains HMO LNT LNnT 2FL 3FL 6SL Mucin Lactose
B. infantis
 ATCC 15697 + + + + + + + + + + + + + + + + + + − + + + 
 ATCC 25962 + + + + + + + + + + + + + + + + + + − + + + 
 ATCC 17930 + + + + + + + + + + + + + + + + + − + + + 
 ATCC 15702 + + + + + + + + + + + + + + + + + − + + + 
 JCM 7007 + + + + + + + + + + + + + + + + + − + + + 
 JCM 7009 + + + + + + + + + + + + + + + + + + − + + + 
 JCM 7011 + + + + + + + + + + + + + + + + + + − + + + 
 SC30 + + + + + + + + + + + + + + + + + − + + + 
 SC97 + + + + + + + + + + + + + + + + + + − + + + 
 SC117 + + + + + + + + + + + + + + + + + − + + + 
 SC142 + + + + + + + + + + + + + + + + + + − + + + 
 SC143 + + + + + + + + + + + + + + + + + − + + + 
 SC145 + + + + + + + + + + + + + + + + + − + + + 
 SC268 + + + + + + + + + + + + + + + + + + − + + + 
 SC417 + + + + + + + + + + + + + + + + + − + + + 
 SC523 + + + + + + + + + + + + + + + + + + − + + + 
 SC569 + + + + + + + + + + + + + + + + + + − + + + 
 SC600 + + + + + + + + + + + + + + + + + + − + + + 
 SC605 + + + + + + + + + + + + + + + + − + + + 
 SC638 + + + + + + + + + + + + + + + + + − + + + 
 SC680 + + + + + + + + + + + + + + + + + + − + + + 
B. bifidum
 JCM 1254 + + + + + + + + + + + + + + + − + + + + + 
 JCM 1255 − + + + − − − − − + + + 
 JCM 1209 + + + + + + + + + + + + + + + − + + − 
 JCM 7002 + + + + + + + + + + + + + + + + + + + + + + + 
 JCM 7003 + + + + + + + + + + + + + + + + + + + + + + + + 
 JCM 7004 + + + + + + + + + + + + + + + 
 S28-a + + + + + + + + + + + + + + + + + − + + + 
 PRL2010 + + + + + + + + + + + + + + + + + + − + + 
 SC112 + + + + + + + + + + + + + + + + + + + + + + 
 SC126 + + + + + + + + + + + + + + + + + + + 
 SC555 + + + + + + + + + + + + + + + + + + + + + + 
 SC572 + + + + + + + + + + + + + + + + + + + + + + + 
 SC583 + + + + + + + + + + + + + + + + + + + + 
B. animalis
 JCM 10602 − − − − − − − + + 
Table 1.  Level of growth on different glycans by B. bifidum and B. infantis strains. aLevel of growth 
was classified as follows: − , negative (maximum OD600 < 0.250); + , low (OD600 from 0.250 to 0.500); + + , 
moderate (OD600 from 0.500 to 0.800); + + + , high (OD600 > 0.800).
www.nature.com/scientificreports/
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deposited in the Integrated Microbial Genome Expert Review annotation platform (https://img.jgi.doe.
gov, GOLD Project ID: Gi17163).
The draft genome of B. bifidum SC555 assembled to 22 contigs with an average length of 101,703 bp 
(Table S6). The SC555 genome totals 2.24 Mbp, with a G + C content of 62.65%. These values are simi-
lar to those observed for other available B. bifidum genomes (Table S6). Analysis of orthologous genes 
shared in strain SC555 and B. bifidum PRL2010 indicates a high degree of similarity (Figure S2). In 
Figure 2. Principal component analysis (PCA) defined by the two principal components (PC1 and 
PC2) of the maximum OD600 values of B. infantis (blue) and B. bifidum (red) growth on HMO, LNT, 
LNnT, 2FL, 3FL, 6SL, mucin and lactose. Negative control, B. animalis (Yellow). (A) represents variables 
(oligosaccharides substrates) and (B) bifidobacteria strains.
www.nature.com/scientificreports/
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addition, unique genes on each genome are mostly hypothetical without a predicted function, associ-
ated with prophages, or restriction-modification systems (data not shown). Finally, B. bifidum SC555, 
PRL2010 and JCM1255 have an identical number of transporters and glycosyl hydrolases previously 
characterized in the context of HMO utilization20,26 (Table S7).
The transcriptomes of B. infantis and B. bifidum in response to HMO. To profile the global 
transcriptional response of B. bifidum and B. infantis to major milk oligosaccharides, two sets of experi-
ments were carried out. First, strains B. infantis ATCC 15697 and B. bifidum SC555 were grown on HMO 
purified from pooled breast milk18. Samples were extracted from duplicate cultures at early, mid and late 
exponential phase of growth (referred to as HMOearly, HMOmid and HMOlate). Second, these two 
strains were cultured on single purified milk oligosaccharides as the sole carbon source: LNT, LNnT, 2 FL, 
3FL, and 6 SL. Sampling was performed at the mid-exponential phase. The two bifidobacterial strains 
were also grown on lactose as a reference sugar, and B. bifidum SC555 was also grown on porcine mucin 
for comparative purposes.
RNA extracted from the above-mentioned samples were depleted of ribosomal RNA and used to 
quantify absolute transcript concentrations using RNA sequencing (RNA-seq). It has been recently esti-
mated that 5–10 million reads is an adequate number to interrogate the bacterial transcriptome with high 
resolution32,33. RNA-seq experiments generated over 365 million reads in total, with each sample aver-
aging 10.4 million reads for B. infantis samples, and 8.8 million reads for B. bifidum. Over 70% of these 
reads aligned to coding genes; 15% aligned to intergenic regions (Table S8). Ribosomal RNA depletion 
led to total average representation of 16S and 23S rRNA transcripts of less than 1%. General features and 
statistics from the RNA-Seq experiments are summarized in Table S8.
We first compared the whole transcriptomes of both species on every glycan substrate and growth 
phase (Fig. 3A,B) using hierarchical clustering. In all RNA-seq experiments conducted on both bifido-
bacterial species, biological replicates were more similar to each other than to other samples as expected. 
For B. infantis, whole transcriptomes in response to 2 FL, 3FL, and 6 SL formed one primary cluster that 
was distinct from lactose (Fig. 3A). In contrast, we found that global transcriptomes of growth on LNT 
and LNnT were much more similar to HMO (Fig.  3A). In addition, temporal responses to growth on 
HMO were also similar among each other, indicating that the initial response mounted to HMO is rather 
stable during exponential growth on HMO.
Unlike B. infantis, the global transcriptional responses of B. bifidum to 2 FL, 3FL, and 6 SL were very 
similar to lactose (Fig.  3B), forming a separate branch in the analysis. Transcriptomes of B. bifidum 
SC555 during growth on HMO at different time points were also closely similar to profiles on LNT, 
LNnT and also mucin. In summary, for both species global transcriptomes of growth of LNT and LNnT 
Figure 3. Whole transcriptome distances in substrate responses of B. infantis (A) and B. bifidum (B). 
The heatmap shows the distances between the B. infantis whole transcriptomes in response to the substrate 
listed: SL6 = 6′ siayllactose, FL3 = 3-fucosyllactose, FL2 = 2′ fucosyllactose, HMOearly = HMO at early time 
point, HMOmid = HMO at mid time point, HMOlate = HMO at late time point, LNT = Lacto-N-tetraose, 
LNnT = Lacto-N-neotetraose, “(.A)” = first biological replicate, “(.B)” = second biological replicate. The 
distances calculated are Euclidian distances of the variance-stabilized count data. The darkness of the blue 
color in the heatmap indicates the degree of similarity, from white (dissimilar) to dark blue (most similar). 
Likewise, the dendograms also show the distances with larger branch lengths indicating greater distances.
www.nature.com/scientificreports/
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resembled more that of pooled HMO at any point during exponential growth, with smaller HMO elic-
iting similar transcriptomes to lactose.
Genes highly expressed in both B. infantis and B. bifidum. Certain genes were highly expressed 
regardless of the growth conditions in both B. bifidum and B. infantis (Tables 2 and 3). These are house-
keeping genes and provide insights into bifidobacterial physiology. These genes include ribosomal pro-
teins and elongation factors used in protein synthesis. Interestingly, the most transcribed locus across all 
samples was RNase P, which is a catalytic RNA that participates in post-transcriptional modification of 
tRNA molecules34. The gene is encoded by BBIF_01522 in B. bifidum and what was previously annotated 
to be an intergenic region in B. infantis22 (coordinates 1,013,344–1014356). Several genes encoding subu-
nits of the F1F0 ATP synthase were also highly expressed (Tables 2 and 3). Other genes, such as a bacterial 
histone-like protein (Blon_0679 and BBIF_00999), chaperonines, and key enzymes of the bifid shunt such 
as fructose-6-phosphate phosphoketolase (Blon_1722 and BBIF_00286) and glyceraldehyde-3-phosphate 
dehydrogenase (Blon_0900 and BBIF_01046) were highly expressed as well.
Comparative transcriptomics of B. infantis in response to different milk oligosaccharides. 
Comparative genomics and functional studies have previously provided a framework of HMO utilization 
in B. infantis and B. bifidum8,20,22,26,35, which includes ABC transporters and uniporters, glycosyl hydro-
lases and feeder pathways. Lists including these genes and their annotations are presented in Tables S9 
and S10. In addition to confirming expression of genes of interest during growth on HMO, RNA-seq 
was used to characterize change in expression in response to specific HMO structures and how these 
responses evolve during exponential growth.
A first subset of genes displayed consistent expression values across all conditions tested (Fig.  4). 
These genes encode important functions such as an ATPase associated to ABC transporters (Blon_2475), 
galactose metabolism genes and a β -galactosidase with lactase activity36, Blon_2334 (Fig. 4 and Table S9).
Among genes associated with HMO consumption in B. infantis (Table S9), RNA-seq confirmed that 
several of them are significantly upregulated during growth on HMO (Fig. 4). This induction was steady 
across exponential growth time points (Fig. 4). These genes are located mostly in the HMO cluster I22 
(Blon_2335 to Blon_2346), and Blon_0881 and Blon_0882, encoding enzymes responsible for GlcNAc 
derivation to the bifid shunt. These results suggest that the HMO cluster I acts as an HMO-inducible 
unit, and that it is co-regulated in a similar fashion with this GlcNAc utilization pathway.
It is interesting to note that these HMO-utilization genes are also induced several fold when B. infan-
tis grows on LNT, LNnT and 6 SL (Fig. 4). While this is expected for LNT, which is the most abundant 
HMO5, and for LNnT which is an isomer of LNT, 6 SL eliciting a similar response to HMO was not 
Feature ID
Mean 
RPKM
SD 
RPKM
Gene 
length Description
NC_1013344_1014356 423108 175222 375 RNAse P
Blon_1922 11971 2505 1356 translation elongation factor Tu(EC:3.6.5.3)
Blon_2257 10261 5063 90 chaperonin Cpn10
Blon_0694 9911 5948 807 chaperonin GroEL
Blon_0679 7198 2063 1437 histone family protein DNA-binding protein
Blon_1722 6147 2759 1302 Fructose-6-phosphate phosphoketolase(EC:4.1.2.22)
Blon_0900 5758 2720 636 glyceraldehyde-3-phosphate dehydrogenase, type I(EC:1.2.1.12)
Blon_1095 5159 1997 4476 transcriptional regulator, Fis family(EC:2.2.1.2)
Blon_0308 4800 1373 1473 ATP synthase F1, gamma subunit(EC:3.6.3.14)
Blon_2152 4479 1208 747 phosphoglycerate mutase 1 family(EC:5.4.2.1)
Blon_0309 4369 1031 294 ATP synthase F1, beta subunit(EC:3.6.3.14)
Blon_1089 4310 978 1119 preprotein translocase, SecG subunit
Blon_2215 4041 1713 2181 translation initiation factor IF-1
Blon_0307 4036 975 924 ATP synthase F1, alpha subunit(EC:3.6.3.14)
Blon_2211 3882 972 912 DNA-directed RNA polymerase, alpha subunit(EC:2.7.7.6)
Blon_2475 3016 1753 450 ABC transporter related, ATPase component
Blon_0382 2871 1094 294 narrowly conserved hypothetical protein
Blon_1738 2421 1455 414 hypothetical protein
Table 2.  Most highly transcribed genes in all datasets in B. infantis.
www.nature.com/scientificreports/
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predicted. LNT and LNnT are GlcNAc containing neutral HMO, while 6 SL contains a negatively charged 
sialic acid residue.
In contrast, the expression of these genes is different when B. infantis consumes 2 FL or 3FL (Fig. 4). 
When growing on these sugars as the sole carbon source, the expression of the HMO cluster dis-
played only basal RPKM values, and other gene clusters appear to be used instead. Genes Blon_0341 to 
Blon_0344, Blon_2202 to Blon_2204 and Blon_2305 to Blon_2309, were induced by 2 FL, 3FL but no 
other substrates. These genes encode functions related to FL import through ABC transporters23, and 
putative enzymes participating in fucose metabolism37 (Table S9). Thus, the transcriptional results sug-
gest that fucosyllactose is imported and catabolized using proteins encoded by these alternative genes.
Differential transcription of key functions of the HMO utilization in B. bifidum. A model has 
been proposed regarding how B. bifidum obtains energetic value from HMO and mucin glycoconju-
gates20,32. Important determinants are extracellular glycosyl hydrolases, that generate mono and disac-
charides that are captured by membrane porters and one ABC transporter, specific for HMO-derived 
lacto-N-biose (LNB) and mucin-derived galacto-N-biose (GNB). This gene set is shown in Table S10.
Some of these genes displayed high expression at all time points during growth on HMO, regardless 
of the substrates used (Fig.  5). These include important determinants in B. bifidum HMO and mucin 
consumption, such as lacto-N-biosidase (BBIF_00533), lacto-N-biose phosphorylase (BBIF_01217), and 
an endo-α -N-acetylgalactosaminidase (BBIF_00503).
Several of these genes were largely induced during growth on HMO compared to lactose. In general, 
this response was stronger during early growth, with lower values to the end of exponential growth, 
including the LNB/GNB ABC transporter cassette and the LNB/GNB utilization pathway (Fig. 5, Table 
S10). Interestingly, these genes were similarly induced during growth on LNT, LNnT and even mucin, 
likely reflecting the importance of LNB and GNB to B. bifidum38.
In contrast, the LNB/GNB cluster and pathway were not induced by 2 FL or 3FL, probably indicating 
that B. bifidum SC555 is mostly unresponsive to these substrates (Fig. 5). This is in agreement with the 
observation that two genes encoding α -fucosidases (BBIF_00008 and BBIF_01261), are actually induced 
by HMO, LNT, LNnT and mucin, but not by 2 FL or 3FL (which contain fucose). Collectively, these 
results suggest that while B. bifidum can use larger fucosylated oligosaccharides, it does not show a pref-
erence for 2 FL or 3FL and it only benefits from the lactose on these oligosaccharides.
Feature ID
Mean 
RPKM
SD 
RPKM
Gene 
length Gene description
BBIF_01522 94,333 49,231 364 RNAse P
BBIF_00180 14,278 9,299 1308 ABC-type sugar transport system, periplasmic component
BBIF_01548 13,101 1,683 1200 translation elongation factor TU
BBIF_00999 8,704 7,171 282 Bacterial nucleoid DNA-binding protein
BBIF_01022 8,602 3,665 1791 ABC-type dipeptide transport system, periplasmic component
BBIF_00527 8,245 5,856 1551 PTS system, N-acetylglucosamine-specific IIBC component
BBIF_00151 7,302 3,843 1104 transaldolase, mycobacterial type(EC:2.2.1.2)
BBIF_01766 6,811 4,378 2376 formate acetyltransferase 1(EC:2.3.1.54)
BBIF_01046 6,234 1,175 1056 glyceraldehyde-3-phosphate dehydrogenase, type I(EC:1.2.1.12)
BBIF_01460 6,138 4,967 2757 Phosphoenolpyruvate carboxylase(EC:4.1.1.31)
BBIF_00286 5,645 3,686 2478 Phosphoketolase(EC:4.1.2.22)
BBIF_00528 5,155 3,411 507 PTS system, glucose subfamily, IIA component(EC:2.7.1.69)
BBIF_01456 4,752 2,330 564 peroxiredoxin(EC:1.11.1.15)
BBIF_01401 4,711 2,056 1128 ABC-type sugar transport systems, ATPase components
BBIF_00570 4,122 2,327 3339 N-acetyl-beta-hexosaminidase(EC:3.2.1.52)
BBIF_00150 3,780 1,866 2109 transketolase, bacterial and yeast(EC:2.2.1.1)
BBIF_00846 3,764 2,111 219 translation initiation factor IF-1
Table 3.  Most highly transcribed genes in all datasets in B. bifidum.
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Indirect comparison of B. infantis and B. bifidum by functional enrichment analysis. In a 
different set of analyses, whole transcriptional responses for both bifidobacterial species were compared 
indirectly by annotating all genes by function using Clusters of Orthologous Groups (COG) of proteins 
functional categories, gene ontology (GO) terms, Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways, and Stanford Research Institute (SRI) pathways54. We next determined which of these pre-
dicted functions were differentially enriched within and between the two species (Tables S11–S15).
The two species displayed different functional enrichments when examining genes up-regulated in 
the presence of HMO at the initial sampling point. During the HMOearly time point relative to lac-
tose, the B. infantis transcriptome is enriched for the GO terms “carbohydrate transport” and “trans-
porter activity” as well as COGs of both components of the ABC-type sugar transport system (Table 
S11). This enrichment was also observed during growth on individual HMO, including 2 FL and 3FL 
(Table S11). In contrast, the B. bifidum transcriptome was not enriched for “carbohydrate transport” until 
HMOlate samples (Table S13). Instead, genes upregulated by B. bifidum at the HMOearly time point 
were enriched for translation (e.g. ribosome, rRNA binding, translation) as well as “cell adhesion” and 
“carbohydrate metabolic process” (Table S13). GO terms and COGs related to carbohydrate transport 
were also enriched in the B. infantis response to individual HMO substrates, but not in the B. bifidum 
response to these substrates (Tables S11 and S13). Interestingly, B. infantis appears to down-regulate 
nucleotide biosynthesis, at the mid and late phase of growth on HMO as well as on LNT relative to 
lactose. These observations support our hypothesis that B. infantis has innovated several parallel systems 
to transport intact milk oligosaccharides. This is in contrast with B. bifidum which deploys a far more 
limited oligosaccharide transport system with a substrate acquisition strategy focused on extracellular 
mono- and disaccharides generated from HMO.
Figure 4. Hierarchical clustering of features (HCF), of the whole transcriptome of B. infantis during 
growth on HMO and major HMO. The heat map represents the expression of genes in Table S9.
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Direct comparison of B. infantis and B. bifidum by orthologs. To directly compare the tran-
scriptional response between the two bifidobacterial species, we identified orthologs for which there 
is a single copy present in each genome (see Methods). Subsequently, we placed all gene expression 
values on this common coordinate system. Between the B. infantis and B. bifidum genomes, 1266 single 
copy orthologs were identified. Of these, between 772 and 1113 were differentially expressed in the two 
species in response to the same substrate (Table S15). In response to each substrate, roughly half of the 
differentially expressed genes are up-regulated in B. infantis, relative to B. bifidum, and the other half 
are up-regulated in B. bifidum, relative to B. infantis (Table S15). Importantly, each species had a distinct 
response to each substrate, even lactose, when comparing the orthologous genes.
Even in situations where the two species have the same genetic capacity (i.e. both have a single copy 
ortholog), the expression of that single ortholog in response to the same substrate varied by nearly 
150-fold. For example, components of the phosphotransferase system exist in both species but are 
up-regulated in B. bifidum 139- to 148-fold compared to B. infantis in response to HMO at the early 
time point (Table S16). Other orthologs are likewise highly expressed in one species and essentially unex-
pressed in the other (Tables S16 and S17). The NLPA lipoprotein (Blon_1721) in B. infantis is 130-fold 
higher than its ortholog in bifidum (BBIF_01591). It is most highly expressed in response to lactose; thus, 
its function is expected to be independent of HMO substrates.
The B. infantis short-chain dehydrogenase/reductase (SDRs) Blon_2339 and Blon_2308, together, are 
expressed 111.9-fold higher than their orthologous gene in B. bifidum, BBIF_01220 (Table S17). These 
genes are probably involved in fucose metabolism37, and are up-regulated in response to HMO relative 
to lactose (p < 2.3e-31). Blon_2308 is uniquely significantly higher, by over 900-fold, in response to 2FL 
relative to lactose (p = 0). These data support the idea of fucose being actively metabolized by B. infantis, 
while B. bifidum seems to prefer other monosaccharides such as Gal, GlcNAc and Glc, cross-feeding 
fucose and sialic acid to other species.
A correlation map of the whole transcriptomes, based on single copy orthologs, for both species on 
all tested substrates is shown in Fig. 6. Perhaps most striking, the B. bifidum response to lactose, 2 FL, 
and 3FL is more similar to B. infantis HMO-late than it is to its own response to HMO, LNT, LNnT, or 
mucin (Fig. 6). In other words, the B. bifidum response to lactose, 2 FL and 3FL correlates poorly with its 
own response to LNT, LNnT, mucin, or HMO at any point. Relative to lactose, there are only 230 and 138 
genes differentially expressed by B. bifidum in response to 2 FL or 3FL, respectively. In contrast, there are 
over a 1000 genes differentially expressed by B. bifidum in response to the other substrates (Tables S18 
and S19). This confirms that B. bifidum has a fundamentally different strategy for uptake and utilization 
of lactose and FL compared to the more complex oligosaccharides.
Discussion
In this study we compared the physiological and transcriptional responses to HMO of two representa-
tives of important species of infant-gut associated bifidobacteria: B. infantis and B. bifidum. Importantly, 
Figure 5. Hierarchical clustering of features (HCF), of the whole transcriptome of B. bifidum during 
growth on HMO and major HMO. The heat map represents the expression of genes in Table S10.
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we determined the transcriptional responses to pooled and single isolated HMO molecules, linking in 
detail biological function with substrate structural diversity.
While almost all B. infantis strains were efficient in utilizing a diversity of HMO as the sole carbon 
source, B. bifidum strains were more variable (Table 1). This is interesting since most of the strains stud-
ied were from infant origin, and it could be expected that they are all competitive in HMO consumption. 
While this was the case for B. infantis, several B. bifidum strains did not show a major preference for 
HMO, indicating that they may target other carbon sources. Growth analysis in Table  1 showed that 
medium and poor HMO-utilizing strains still display the ability to grow on LNT or mucin. It is very 
interesting to note that key HMO genes (lacto-N-biosidase, galactosidases, fucosidases and sialidases; 
Figure 6. Map of correlations between orthologous transcriptomes in B. infantis and B. bifidum. Each 
box in the heatmap represents the correlation between the transcriptomes indicated on the x-axis and y-axis: 
BLON = B. infantis, BBIF = B. bifidum, SL6 = 6′ siayllactose, FL3 = 3′ fucosyllactose, FL2 = 2′ fucosyllactose, 
HMOearly = HMO at early time point, HMOmid = HMO at mid time point, HMOlate = HMO at late 
time point, LNT = Lacto-N-tetraose, LNnT = Lacto-N-neotetraose “(.A)” = first biological replicate, 
“(.B)” = second biological replicate. The color key indicates the correlation also indicated by the text in each 
box: The color key also includes a light blue line that indicates the number of observations at each level of 
expression.
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Table S7), are present in the same numbers in high growers (SC555) and poor growers (JCM 1255), 
indicating that the physiological differences among these strains are due to point mutations or differential 
regulation of these genes. In addition to the implications to host-microbial interactions, this wide array 
of responses to HMO has the potential to impact applications such as probiotic design, where strain-level 
differences in substrate utilization require additional consideration. Another recent study studied a sim-
ilar number of B. breve strains, showing that certain of these isolates were much more competitive in 
different HMO consumption than previously reported for the type strain21.
In this study we used RNA-sequencing for determining the global transcriptome of B. infantis and B. 
bifidum during the in vitro consumption of specific, structurally different HMO, and during exponential 
growth. While our group and others have determined certain genes participating in HMO consumption 
in both species, in this study we were able to screen how individual HMO elicit differential transcrip-
tomes in both bifidobacteria.
An important observation is that B. infantis and B. bifidum have a markedly different physiological 
response to FL. Genetic factors (secretor genes) such as the α 1,2 fucosyltransferase (FUT2) and α 1,3/4 
fucosyltransferase (FUT3) genes can significantly alter HMO composition39,40, especially increasing the 
abundance of 2 FL and α 1-2 fucosylated HMO. The impact of milks higher or lower in 2 FL on bifido-
bacterial species is still not clear, although certain studies suggest a correlation between secretor status 
and the overabundance of certain bifidobacterial species41.
In B. infantis, we have observed that 2 FL or 3FL induces the expression of discrete, alternative oper-
ons, distinct from the HMO cluster I. They contain functions related to fucosylated HMO import and 
fucose utilization, and interestingly are not induced by pooled HMO or single neutral HMO. In contrast, 
global transcriptomes of LNT and LNnT in both species were highly similar to HMO, and responses 
to HMO were mostly steady during in vitro growth. Noteworthy, several HMO species such as LNT 
or LNnT enhanced the expression of several HMO consumption genes in a similar manner as pooled 
HMO. This was evident in the acidic 6 SL as well. It is possible that the transcriptomes in response to 
neutral HMO and 6 SL are similar considering that sialic acid and GlcNAc metabolic feeder pathways are 
convergent in B. infantis31. Neu5Ac is metabolized to GlcNAc-6-P and later to fructose-6-P in Escherichia 
coli and Bifidobacterium breve42,43, and the respective genes were upregulated during growth on these 
substrates (Fig. 4, Table S9).
This transcriptional analysis was also useful in providing additional detail on both mechanistic mod-
els of HMO consumption deployed by infant-associated bifidobacteria. The similarity of transcriptomes 
in response to 2 FL, 3FL, 6 SL and lactose suggests that B. bifidum SC555 appears to prefer the utilization 
of lactose when growing on short HMO, probably releasing fucose and sialic acid to the environment. 
This in turn might allow cross-feeding to other gut species. This has been recently shown using mucin 
oligosaccharides and 3 SL43,44, where B. breve can feed on sialic acid released from B. bifidum activity. 
This is supported by the absence or lack of activation of fucose and sialic acid metabolic pathways in the 
genome or transcriptome of B. bifidum SC555 (Table S10). In contrast, B. infantis seems to activate feeder 
pathways for fucose and sialic acid (Fig. 4 and Table S9) during most of the conditions tested, reflecting 
its ability to further process these monosaccharides.
Finally, global transcriptome analysis and ortholog comparison presented another set of fundamental 
differences between each species’ physiology. While we expected to observe an induction of carbohy-
drate transport and metabolism genes in B. infantis, this upregulation was just modest in B. bifidum 
SC555 especially during growth on FL (Tables S16 and S17). We also noted that expression of several 
orthologous genes was also drastically different, which indicates that both species operate and respond 
differently to HMO. For example, while the HMO utilization strategy in B. bifidum relies in part on a PTS 
system, the corresponding homolog in B. infantis does not appear to participate in this process. Putative 
fucose metabolism genes were in contrast induced several fold only in B. infantis.
The differences presented therefore reflect two different lifestyles found in the infant intestinal 
microbiome that have apparently converged in specialization in utilization of HMO. It could be possible 
that both B. bifidum and B. infantis display biogeographical differences as well, considering that most 
B. bifidum strains are competitive in mucin degradation, associating this species with the mucus layer. 
In contrast, B. infantis could reside mostly in the lumen. Certain species in the gut microbiome, such as 
Clostridium and Bacteroides, can be preferentially located in the mucus layer or the intestinal lumen45.
Conclusions
Both B. infantis and B. bifidum are able to utilize HMO as a sole carbon source, but with divergent strat-
egies. In the present study, we showed that B. infantis strains are highly homogeneous in their ability 
to use specific HMO substrates, while B. bifidum isolates were more diverse, with some strains unable 
to grow on fucosylated or sialylated HMO. Choosing representative strains that grow well on HMO, we 
confirm that B. infantis expresses an assortment of transporters to internalize HMO substrates while B. 
bifidum expresses enzymes to hydrolyze HMO extracellularly. The transcriptome of each isolate varies 
dramatically even in response to structurally similar substrates. Likewise, the two strains have different 
transcriptional responses to the same substrate, even when lactose is the sole carbon source.
Our findings highlight the genetic and functional diversity between strains and between different 
isolates of the same strain as well as the specific mechanisms used by these isolates to utilize HMO. 
Such detailed mechanistic knowledge of the relationships between substrates and specific bifidobacteria 
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will inform effective prebiotic and probiotic strategies. Synbiotic supplements could be designed to pair 
specific prebiotics with probiotics that will consume them via known strategies to achieve predefined 
functional outcomes.
Methods
Bacteria and media. Bifidobacterium strains used in this study (Table S1) were obtained from fecal 
samples from exclusively breast-fed term infants21, the Japanese Collection of Microorganisms (Riken 
Biosource Center Japan), the American Type Culture Collection (Manassas, VA), and the University 
of California Davis Viticulture and Enology Culture Collection (Davis, CA). For routine experiments, 
bifidobacteria were grown on de Mann-Rogose-Sharp (MRS) broth supplemented with 0.05% w/v 
L-cysteine (Sigma-Aldrich, St. Louis, MO), and incubated for 18 h at 37 °C in an anaerobic chamber (Coy 
Laboratory Products, Grass Lake, MI), in an atmosphere containing 5% carbon dioxide, 5% hydrogen, 
and 90% nitrogen. Prior to each assay all bacteria were subcultured twice.
Multilocus sequence typing (MLST) of strains. MLST analysis of B. infantis and B. bifidum strains 
targeted intragenic regions of seven housekeeping genes clpC, purF, gyrB, fusA, Iles, rplB, rpoB that were 
selected based on a previous study27. For PCR amplification, one μ l of extracted DNA was added to 50 μ l 
reaction mixture containing 50 pmol of primers, 200 μ M of each dNTP, 0.1 vol of 10X PCR buffer, 2.5 mM 
MgCl2, and 1 U AmpliTaq gold polymerase (Applied Biosystems). Cycling conditions were optimized 
for every primer set (Table S2) and consisted of an initial denaturation at 95 °C for 4 min, followed by 
35 cycles of 95 °C for 30s, annealing at 60–67 °C for 30s, elongation at 72 °C for 60s, final extension at 
72 °C for 7 min, and holding at 4 °C. The resulting amplicons were separated using a 1% agarose gel, fol-
lowed by GelRed staining (Phenix Research Products, Candler, NC), and purification using a QIAquick 
PCR Purification Kit (Qiagen, Valencia, CA). Sequencing was performed on an ABI 3730 Capillary 
Electrophoresis Genetic Analyzer using BigDye Terminator chemistries at the University of California 
Davis DNA Sequencing Facility. Sequencing data for all loci was edited using BioEdit 7.0 and aligned 
using CLUSTAL W46. Phylogenetic analysis and concatenations of the sequenced loci were performed 
using the Molecular Evolutionary Genetic Analysis (MEGA) software version 5 (http://megasoftware.
net). Descriptive evolutionary analysis including mol% G + C content, number of polymorphic sites, 
nucleotide diversity π /site, average number of nucleotide differences k were calculated using DnaSP 
version 5.10 (Table S3). Allelic sequences were assigned as described previously47 (Tables S4 and S5). A 
minimum evolution tree of the concatenated loci was calculated using MEGA 5.0 (Fig. S1).
Bifidobacterial growth in vitro on HMO. The 35 bifidobacterial strains in Table S1 were tested 
for growth in the presence of seven different substrates: HMO18, LNT, lacto-N-neotetraose (LNnT), 
2′ -fucosyllactose (2 FL), 3-fucosyllactose (3FL) (Glycom, Denmark), 6′ -sialyllactose (6 SL) (GenChem 
Inc. Korean), and hog mucin type II (Sigma). B. animalis subsp. lactis JCM 10602 was also included as 
negative control for growth experiments. Two μ l of each resulting overnight culture were used to inoc-
ulate 200 μ l of modified MRS medium (mMRS), devoid of glucose and supplemented with 2% (w/v) of 
each substrate, except for mucin at 1%, as the sole carbohydrate source, and another 2 μ l inoculated into 
mMRS without added sugar. Mucin was autoclaved at 121 °C for 10 minutes before addition to broth. The 
media was supplemented with 0.05% (w/v) L-cysteine, and in all the cases the cultures in the wells of the 
microtiter plates were covered with 30 μ l of sterile mineral oil to avoid evaporation. The incubations were 
carried out at 37 °C in an anaerobic chamber (Coy Laboratory Products, Grass Lake, MI). Cell growth 
was monitored in real time by assessing optical density (OD) at 600 nm using a BioTek PowerWave 340 
plate reader (BioTek, Winoosky, VT) every 30 min preceded by 15 seconds shaking at variable speed. 
Two biological replicates and three technical replicates were performed for every studied strain. The OD 
obtained for each strain grown on the different substrates, was compared with the OD obtained in the 
absence of a sugar source. This difference in OD (Δ OD) was used as a parameter to evaluate each strain’s 
ability for growing on the different substrates.
Statistical analysis of growth. Statistical analysis of the data was carried out using SPSS for 
Windows, 15.0 (SPSS Inc Chicago, IL, USA). The relationships among the maximum OD600 values of 
the growth on the different substrates by the bifidobacteria strains were evaluated by Pearson correlation 
coefficients and principal components analysis (PCA).
Genome sequencing. B. bifidum SC555 is a strain that was previously isolated from a 3–6 month 
old infant. For genome sequencing, the strain was grown on MRS broth under the anaerobic conditions 
described above. After 18 h, 5 ml of this culture was centrifuged at 12000 × g for 2 min, and used to 
extract DNA using the MasterPure Gram-positive DNA Purification Kit (Epicentre), following manu-
facturer instructions. DNA was quantified using the dsDNA HS Assay in a Qubit 2.0 fluorometer (Life 
Technologies, Carlsbad CA). DNA was also checked for integrity in 1% agarose gels. Next, 2 μ g of the 
genomic DNA in 100 μ l of elution buffer EB were sonicated in a Bioruptor Standard (Diagenode, Denville 
NJ), for 10 min with cycles of 30s on and 30s off. Samples were stored at − 20 °C, and fragmentation sizes 
were evaluated in a 2100 Bioanalyzer using the Agilent DNA 1000 kit (Agilent Technologies, Santa Clara 
CA). Fragmented cDNA (15 μ l at 20 ng/μ l) was used to prepare a library for Illumina sequencing using 
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the Apollo 324 Robot and the PrepX ILM DNA Library Kit (IntegenX, Pleasanton CA), at the Genome 
Center at UC Davis and following manufacturer instructions. Sample was ligated with BiooScientific 
Adapter 15 (Bioo Scientific, Austin TX). The resulting library was checked for size using a High Sensitivity 
DNA Kit (Agilent) in the Bioanalyzer 2100, with an expected average size of 350 bp. Finally, sample was 
pooled with other seven bacterial genomes at the Genome Center at UC Davis DNA Technologies Core 
Facility, for sequencing on a Illumina HiSeq2500. All sequencing steps were carried out by Core person-
nel. Sequencing was run for 200 cycles, with read length of 100 bp (paired ends).
Sequencing files were concatenated using Terminal, and processed for genome assembly using 
CLC-Bio Genomics Workbench (Cambridge, MA). Reads (100 bp) were trimmed setting at 2 the max-
imum of ambiguous base pairs, and deleted if their quality scores were below 0.5. Edited reads were 
next aligned to the genome sequence of Bifidobacterium bifidum PRL2010. Genbank files were obtained 
from the Integrated Microbial Genome database48. Resulting contigs from the genome of B. bifidum 
SC555 were submitted to the IMG Expert Review (IMG/ER) for annotation (GOLD card: Gi17163. ER 
submission ID: 8631). Locus tags generated contained the BBIF prefix, and topology was linear. Gene 
calling method was the Isolate Genome Gene Calling. Draft genome sequences were analyzed using the 
IMG Expert Review functions. For creating a Venn diagram, Genome Gene Best Homologs between 
Bifidobacterium bifidum SC555 and PRL2010 was used. Analysis was set to look for homologs using 
BLASTP with more than 60% identity at the aminoacid level. The final draft genome of Bifidobacterium 
bifidum SC555 is available at https://img.jgi.doe.gov, GOLD Project ID: Gi17163.
RNA-seq
Sample preparation, growth curves. B. longum subsp. infantis ATCC 15697 and B. bifidum SC555 
were grown as described above in mMRS supplemented with either 2% lactose, 2% HMO, 2% LNT, 2% 
LNnT, 2% 2 FL, 2% 3FL, 2% 6 SL or 1% porcine mucin in a microplate reader, and cultures were taken 
at mid-exponential phase OD 0.5–0.6. In the case of HMO, the samples were collected at three different 
points in the growth curve, approximately OD600nm = 0.25 (early exponential), 0.5–0.7 (mid exponential) 
and 0,9-1.1 (late exponential). Samples were immediately pelleted at 12000 × g for 1 min and stored in 
RNAlater Ambion. RNA extraction, and cDNA conversion were performed as previously described23.
RNA extraction. One ml of each sample stored in RNAlater, with OD above 0.6, was used in the 
procedure. Samples were centrifuged at 10,000 × g for 2 min on a bench centrifuge to collect the cell 
pellet. Pellet was washed twice with PBS buffer to remove RNAlater, and centrifuged at 10,000 × g. 
Pellets were later resuspended in 250 μ l of lysozyme (50 mg/ml final; Sigma) and 125 μ l of mutanoly-
sin (1000 units/ml; Sigma), previously prepared and filter-sterilized in TE buffer (10 mM Tris, 1 mM 
EDTA, pH 7.2). Samples were incubated at 37 °C for 10 min. Pre-lysed cells were centrifuged at 8000 × g 
for 1 min, and the Ambion RNAqeous kit (LifeTechnologies) was used to extract total RNA following 
manufacturer instructions and eluting the RNA in 50 μ l of EB buffer. Total RNA was immediately sub-
jected to DNase treatment with the Turbo DNase free (Ambion) using 3 μ l of DNase I for 1 hour. RNA 
was stored at − 80 °C at this point, but previously quantified in Qubit using the Qubit High Sensitivity 
RNA Assay Kit (Life Technologies). One μ l of RNA was the minimum used in next steps. RNA integ-
rity was checked in a Bioanalyzer using an Agilent RNA Nano Chip. RNA (1–2 μ l) was first denatured 
at 65–70 °C for 2 min before the run. Samples were further processed only if their RIN (RNA Integrity 
Number), was above 7. We later evaluated genomic DNA contamination by qPCR, using the Fast 
Sybr-Green Master Mix (Applied Biosystems, Foster City CA), and universal bacterial primers Uni334F 
(5′ ACTCCTACGGGAGGCAGCAGT) and Uni514R (5′ ATTACCGCGGCTGCTGGC). Template DNAs 
were the RNA samples before and after DNAse treatment, and proper negative and positive controls 
were used. Each reaction (20 μ l total) included 1X master mix, 0.1 μ m primers, and 1 μ l RNA. Samples 
were run in triplicate.
Ribosomal RNA depletion was achieved using the Ribo-Zero magnetic kit, Bacteria (Epicentre, 
Madison WA). Manufacturer instructions were followed (using 28 or 26 μ l of RNA depending on 
the concentration). mRNA was purified with the Qiagen RNeasy Minelute Cleanup kit, following the 
instructions presented in the Ribo-Zero protocol for this part. RNA was eluted in 13 μ l. One μ l of the 
RNA was checked for removal of 16S and 23S rRNA peaks using the Qubit HS RNA Assay (Agilent). 
Chromatograms were manually inspected.
mRNA was later converted to cDNA. For first strand cDNA conversion, the Superscript II Reverse 
Transcriptase was used (Invitrogen), following manufacturer protocol. Reaction also contained Random 
Primers (3 μ g/μ l, Invitrogen). We used 11 μ l of rRNA depleted RNA, 1 μ l of 10 mM dNTPs and 1 μ l 
of random primers. After this, second cDNA strand was synthesized using the NEB NEBNext mRNA 
Second Strand Synthesis Module (New England Biolabs, Ipswich, MA) following manufacturer instruc-
tions. Then, the MinElute Reaction Cleanup Kit (Qiagen, Valencia CA) was used for cleaning up the 
DNA. Final elution was done in two rounds of 15 μ l in EB buffer. At this point cDNA was quantified 
using the Qubit High Sensitivity DNA kit (Life Technologies), and diluted to a volume of 100 μ l with 
EB buffer, for fragmentation in a Bioruptor (Diagenode). Eight cycles of 15s on and 90s off were used 
for each sample. Fragmented cDNA was quantified with Qubit High Sensitivity DNA kit. DNA was also 
analysed in a Bioanalyzer with the Agilent High Sensitivity DNA kit. An average fragment length of 
300–500 bp was desired for next steps.
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Library construction. Sequencing libraries were prepared using the BiooScientific NEXTflex Chip 
Seq Kit (Bioo Scientific, Austin TX). This kit is Illumina compatible. Ten ng of fragmented cDNA were 
used. In the manufacturer protocol, option 3 was followed entirely, with the goal to select fragments 
between 300 and 400 bp in a gel-free protocol. Size selection and clean-up steps were achieved using the 
Agencourt Ampure XP beads (Beckman Coulter, Brea CA), and a Magnetic Stand-96 (LifeTechnologies). 
All temperature-sensitive reactions were carried out in a preheated thermocycler. Adapters used 
(NEXTflex™ ChIP-Seq Barcodes, Bioo Scientific) contained 6-bp indexes for multiplexing. At the last 
step, ligation products were amplified by PCR with the supplied reagents for 17 cycles.
Libraries were first assessed in Bioanalyzer using a DNA high sensitivity Agilent chip. Sizes were 
expected to be in the 300–500 bp range. Libraries were quantified using the Kapa SYBR FAST Universal 
qPCR Kit. At maximum, 24 libraries with different barcodes were pooled in one reaction tube contain-
ing 20 ng of each library. The library was further assessed in an Agilent High Sensitivity DNA kit and 
quantified by Qubit HS DNA assay. Pooled libraries were submitted to the Genome Center at UC Davis 
Genome Center DNA Technologies Core Facility, for sequencing on a Illumina HiSeq2500. All sequenc-
ing steps were carried out by Core personnel. Sequencing was run for 50 cycles, with read length of 50 bp 
(single reads). Runs were demultiplexed by the Core Facility.
Received files were first joined using the Terminal software, and exported to the CLC-Bio Genomics 
Workbench. This platform was used in all analyses unless mentioned. Reads (100 bp) were trimmed set-
ting at 2 the maximum of ambiguous base pairs, and deleted if their quality scores were below 0.5. Edited 
reads were aligned to fasta files generated at IMG from the genome sequences (reference) of B. longum 
subsp. infantis ATCC 15697, and B. bifidum SC555, respectively. Only coding regions were considered in 
this analysis. Alignment allowed a maximum of 2 mismatches, and a maximum of 10 matches to other 
reads. Other settings were considered as default. The CLC-BIO tools retrieved information regarding the 
gene length, total and unique gene reads aligning to a specific locus tag, and automatically calculated the 
RPKM value (Reads Per Kilobase per Million mapped reads)49.
Statistical analysis. RPKM information for each gene in each genome was used in CLC-Bio 
Genomics Workbench for statistical comparisons, under the Set Up Experiment option. This included 
each sample corresponding to B. infantis or B. bifidum growing on a different substrate or growth phase. 
Samples were considered as independent or unpaired (multi-group comparison). RPKM values were 
transformed to log10 for statistical analysis. In box plots, the box is defined by the inter quartile ranges 
(IQR), the median is drawn as a line in the box, and the whiskers extend 1.5 times the height of the box. 
Principal component analysis is presented on transformed values for each sample, including the biolog-
ical replicates. Statistical analyses were carried out on proportion-based Baggerly test50. Samples from 
growth on lactose were considered as reference controls. p-values were applied the Bonferroni correction. 
Finally, hierarchical clustering of features was calculated on original RPKM values, considering Euclidean 
distance and Single cluster linkage.
Differential expression. To determine differentially expressed genes, the R package “DESeq51” was 
applied to the raw count data. Genes with a mean count less than 200 were excluded from analysis. 
Adjusted p-values < = 0.05 were deemed statistically significant. Where a singular p-value has been 
stated in the manuscript for a group of tests, the highest (least significant) p-value is reported.
Functional enrichment analyses. For each substrate group, genes were ranked by their log2fold-
change and p-value for gene expression relative to lactose. Those with a non-significant p-value received 
a rank of 0 (effectively ending up in the middle of the list) while those with a significant p-value received 
a rank equal to their log2 fold change. Up-regulated genes appear towards the top of the list while 
down-regulated genes appear toward the bottom of the list. The ranked gene lists were analysed using 
Gene Set Enrichment Analysis (GSEA)52 for enrichment with functional annotations towards the top of 
the list (e.g. those most differentially expressed). Custom scripts were developed to create GSEA input 
files for different functional annotations. Functional annotations tested included COG functions, KEGG 
pathways, GO terms, and SRI pathways. GO annotations were derived for each gene using Blast2GO53. 
SRI pathway annotations were mapped using SRI Pathway Tools54.
Availability of supporting data
The Bifidobacterium longum subsp. infantis ATCC 15697 genome used in this manuscript is available 
in the Integrated Microbial Genomes database at the Joint Genome Institute at https://img.jgi.doe.gov, 
GOLD Project ID: Gc00886. The Bifidobacterium bifidum SC555 genome is also available at https://img.
jgi.doe.gov, GOLD Project ID: Gi17163. The data from the B. infantis and B. bifidum RNA-sequencing 
studies are available in the NCBI Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/
geo/) with accession numbers GSE58773 and GSE59053, respectively.
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Erratum: Comparative 
transcriptomics reveals key 
differences in the response to milk 
oligosaccharides of infant gut-
associated bifidobacteria
Daniel Garrido, Santiago Ruiz-Moyano, Danielle G. Lemay, David A. Sela, J. Bruce German 
& David A. Mills
Scientific Reports 5:13517; doi: 10.1038/srep13517; published online 04 September 2015; updated on 02 
November 2015
This Article contains typographical errors in Table 1.
For the B. bifidum, JCM1209 strain under ‘HMO’, ‘2FL’ and ‘3FL’, the level of growth should read ‘+ ’, 
‘+ + ’ and ‘+ ’ respectively.
In addition, for the B. bifidum PRL2010 strain under ‘6SL’ and ‘Mucin’, the level of growth should read 
‘-’ and ‘+ + ’ respectively.
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